The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT06083961

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Sun U. Kwon (from the registry)
Registry
  • NCT NCT06083961
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06083961. Non-randomized; no masking; primary purpose treatment. Start 2023-10-15 (anticipated); primary completion 2026-10-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
Condition
Stroke, Acute Ischemic
Condition
PCSK9 Inhibitor
Intervention (Drug)
Alirocumab
Lead sponsor
Sun U. Kwon (class: other)

Record details

Record id
cardio:ct-nct06083961
Content hash
81044cff7fba0429d6c6c6abb72553cb51317e70c1fe25f831ee5eaa06f0312d